论文部分内容阅读
目的探讨培美曲塞联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效及对患者血清炎性因子水平的影响。方法选取2014年2月—2017年2月安阳市肿瘤医院74例晚期NSCLC患者,随机数字表法分组,各37例。对照组采取吉西他滨+顺铂治疗,观察组采取培美曲塞+顺铂治疗,两组均治疗2个周期(6周)。检测对比两组治疗前、治疗2个周期结束时血清炎性因子指标[白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)]水平并统计两组治疗总有效率、毒副反应发生率。结果观察组治疗2个周期结束时IL-6、TNF-α水平均较对照组降低,差异有统计学意义(P<0.05);治疗2个周期后,观察组总有效率45.95%(17/37)与对照组37.84%(14/37)相比,差异无统计学意义(P>0.05);观察组治疗期间Ⅲ~Ⅳ级消化道反应、白细胞减少发生率分别为2.70%(1/37)、2.70%(1/37),均较对照组降低,差异有统计学意义(P<0.05)。结论联合应用培美曲塞与顺铂治疗晚期非小细胞肺癌疗效肯定,可明显减轻机体炎症反应,减少毒副反应发生情况。
Objective To investigate the efficacy of pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC) and its effect on serum inflammatory factors. Methods From February 2014 to February 2017, 74 patients with advanced NSCLC in Anyang Tumor Hospital were randomly divided into three groups, 37 cases in each group. The control group was treated with gemcitabine + cisplatin, and the observation group was treated with pemetrexed + cisplatin. Both groups were treated for 2 cycles (6 weeks). The levels of IL-6 and TNF-α in the two groups before treatment and at the end of the two treatment cycles were measured and compared. The total effective rate, the total effective rate The incidence of side effects. Results The levels of IL-6 and TNF-α at the end of the two treatment periods in the observation group were significantly lower than those in the control group (P <0.05). After 2 cycles of treatment, the total effective rate in the observation group was 45.95% (17 / 37), compared with 37.84% (14/37) in the control group, there was no significant difference (P> 0.05). The incidence of grade Ⅲ ~ Ⅳ digestive tract reaction and leukopenia in the observation group was 2.70% (1/37 ) And 2.70% (1/37) respectively, which were significantly lower than those in control group (P <0.05). Conclusions The combination of pemetrexed and cisplatin in the treatment of advanced non-small cell lung cancer is effective, which can significantly reduce the body’s inflammatory response and reduce the incidence of side effects.